Veracyte (VCYT) Operating Expenses (2012 - 2026)

Veracyte has disclosed Operating Expenses across 15 years of filings, most recently posting $78.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $78.5 million, up 2.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $306.7 million (up 5.21% YoY), and the FY2025 annual result was $304.8 million, up 8.07% from the prior year.
• Operating Expenses came in at $78.5 million for Q1 2026 at Veracyte, up from $64.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $100.3 million in Q4 2023 to a low of -$35.1 million in Q4 2022.
• The 5-year median for Operating Expenses is $76.6 million (2025), against an average of $72.3 million.
• Across the five-year window, Operating Expenses sank 144.1% in 2022 and soared 385.43% in 2023, its largest moves.
• Veracyte's Operating Expenses stood at -$35.1 million in 2022, then jumped by 385.43% to $100.3 million in 2023, then declined by 25.64% to $74.6 million in 2024, then fell by 13.14% to $64.8 million in 2025, then climbed by 21.2% to $78.5 million in 2026.
• The last three Operating Expenses figures came in at $78.5 million (Q1 2026), $64.8 million (Q4 2025), and $68.3 million (Q3 2025), per Business Quant data.